Walmart announces cheaper insulin for diabetics who cannot pay for more expensive versions

Image Credit Walmart

 

 

On Tuesday, Walmart announces that it will be selling a cheaper version of insulin through its pharmacies and membership-based Sam’s Clubs. The vials and pre-filled insulin pens will be available soon. The retail giant said that it was launching this product to help millions of Americans who have no health insurance and for those who struggle to pay for this essential diabetic drug.

 

The retailer will begin selling an exclusive label this week. The insulin analog, called ReliOn Novolog, will be available for both adults and children who have a prescription. It will be available through its membership-based Sam’s clubs by the middle of next month.

 

Walmart has an older low-price version of insulin as a part of the ReliOn line. However, some doctors believe that this version is not as good as the newer versions of insulin called analog, which is better in managing blood sugar swings.

 

Dr. Cheryl Pegus, executive vice president of health and wellness at Walmart said that the retailer has worked directly with the analog insulin manufacturer Novo Nordisk to reduce costs. Pegus also said that its price difference, when compared with branded products, would be up to $101 per vial and $251 for one pack of pre-filled insulin pens.

 

So, how will Walmart manage to cut costs so dramatically? It will do so by sheer volume of sales as well as due to almost no marketing costs as the insulin will be added to an already existing inventory. Walmart has been looking to expand its footprint into diverse markets and the health and wellness market is one of the largest, always growing markets across the world.

 

Yet, it is a market with a lot of risks. Many huge conglomerates and partnerships have tried to disrupt health care with lower costs but have been pushed to the curb. Although, it is lucrative market, it also has its own challenges.

 

Diabetes is a common disease in the United States of America. The numbers of people diagnosed keeps increasing but costs of medicines have also been increasing proportionately, despite the larger market for drugs. Walmart is looking for a share in this huge market which does not as yet have any dominant low cost or medium cost insulin provider.

 

Click Here For Full Stock Research on Walmart by CWEB


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>